UY29938A1 - Derivados de pirido-, pirazo- y pirimido-pirimidina y su uso como inhibidores de mtor - Google Patents

Derivados de pirido-, pirazo- y pirimido-pirimidina y su uso como inhibidores de mtor

Info

Publication number
UY29938A1
UY29938A1 UY29938A UY29938A UY29938A1 UY 29938 A1 UY29938 A1 UY 29938A1 UY 29938 A UY29938 A UY 29938A UY 29938 A UY29938 A UY 29938A UY 29938 A1 UY29938 A1 UY 29938A1
Authority
UY
Uruguay
Prior art keywords
pirimido
pirimidina
pirazo
pirido
derivatives
Prior art date
Application number
UY29938A
Other languages
English (en)
Spanish (es)
Inventor
Graeme Cameron Murray Smith
Gesine Johanna Hermann
Xiao-Ling Fan Cockcroft
Heather Mary Ellen Duggan
Karine Malagu
Keith Allan Menear
Sylvie Gomez
Marc Geoffrey Hummersone
Original Assignee
Kudos Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37533284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29938(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0524047A external-priority patent/GB0524047D0/en
Application filed by Kudos Pharm Ltd filed Critical Kudos Pharm Ltd
Publication of UY29938A1 publication Critical patent/UY29938A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
UY29938A 2005-11-22 2006-11-21 Derivados de pirido-, pirazo- y pirimido-pirimidina y su uso como inhibidores de mtor UY29938A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73890205P 2005-11-22 2005-11-22
GB0524047A GB0524047D0 (en) 2005-11-25 2005-11-25 Compounds
US82330906P 2006-08-23 2006-08-23
US82330806P 2006-08-23 2006-08-23

Publications (1)

Publication Number Publication Date
UY29938A1 true UY29938A1 (es) 2007-06-29

Family

ID=37533284

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29938A UY29938A1 (es) 2005-11-22 2006-11-21 Derivados de pirido-, pirazo- y pirimido-pirimidina y su uso como inhibidores de mtor

Country Status (15)

Country Link
US (1) US20080194546A1 (enExample)
EP (1) EP1954699B1 (enExample)
JP (1) JP5161102B2 (enExample)
KR (1) KR101464384B1 (enExample)
AR (1) AR057626A1 (enExample)
AU (1) AU2006318948B2 (enExample)
CA (1) CA2628920C (enExample)
EC (1) ECSP088536A (enExample)
HR (1) HRP20120963T1 (enExample)
IL (1) IL191196A (enExample)
NO (1) NO341055B1 (enExample)
PL (1) PL1954699T3 (enExample)
TW (1) TWI452047B (enExample)
UY (1) UY29938A1 (enExample)
WO (1) WO2007060404A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2395386T3 (es) 2005-12-21 2013-02-12 Abbott Laboratories Compuestos antivirales
RU2441869C2 (ru) * 2005-12-21 2012-02-10 Эбботт Лэборетриз Противовирусные соединения
MX2009001946A (es) * 2006-08-23 2009-03-05 Kudos Pharm Ltd Derivados de 2-metilmorfolin-pirido-, pirazo- y pirimido- pirimidina como inhibidores de mtor.
UA96304C2 (en) * 2006-08-23 2011-10-25 Кудос Фармасьютикалз Лимитед 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2094276A4 (en) 2006-12-20 2011-01-05 Abbott Lab ANTIVIRAL COMPOUNDS
WO2009039140A1 (en) * 2007-09-17 2009-03-26 Smithkline Beecham Corporation Pyridopyrimidine derivatives as pi3 kinase inhibitors
CN101896180A (zh) * 2007-10-15 2010-11-24 阿斯利康(瑞典)有限公司 组合059
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2262504A1 (en) * 2008-02-21 2010-12-22 AstraZeneca AB Combination therapy 238
ES2398423T3 (es) * 2008-06-20 2013-03-19 Astrazeneca Ab Composiciones con y procedimiento para pirido[2,3-D]pirimidinas sustituídas con metilmorfolina
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
CA2729045A1 (en) * 2008-07-31 2010-02-04 Philippe Bergeron Pyrimidine compounds, compositions and methods of use
EP2349275B1 (en) * 2008-10-31 2017-03-08 Novartis AG Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor.
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
CN102665700A (zh) 2009-11-18 2012-09-12 诺瓦提斯公司 治疗实体瘤和其它恶性肿瘤的方法和组合物
WO2011067348A2 (en) 2009-12-03 2011-06-09 Novartis Ag Mek inhibitor salts and solvates thereof
WO2011067356A2 (en) 2009-12-03 2011-06-09 Novartis Ag Polymorphs of a mek inhibitor
AR080643A1 (es) 2010-02-03 2012-04-25 Signal Pharm Llc Identificacion de la mutacion de lkb1 como un biomarcador predictivo para la sensibilidad a inhibidores de la tor quinasa
EP2539337A1 (en) * 2010-02-22 2013-01-02 F. Hoffmann-La Roche AG Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
JP2013523678A (ja) 2010-03-30 2013-06-17 ノバルティス アーゲー 慢性的に活性なｂ細胞受容体シグナル伝達を有するｂ細胞リンパ腫の治療用のｐｋｃ阻害薬
CA2794952C (en) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
ES2689177T3 (es) 2010-04-13 2018-11-08 Novartis Ag Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer
EP2585454A1 (en) 2010-06-25 2013-05-01 Novartis AG Heteroaryl compounds and compositions as protein kinase inhibitors
WO2012099581A1 (en) 2011-01-19 2012-07-26 Takeda Pharmaceutical Company Limited Dihydrofuropyrimidine compounds
CA2843887A1 (en) 2011-08-03 2013-02-07 Signal Pharmaceuticals, Llc Identification of gene expression profile as a predictive biomarker for lkb1 status
CN102911172A (zh) * 2011-08-04 2013-02-06 上海恒瑞医药有限公司 杂芳基并嘧啶类衍生物、其制备方法和用途
CN103374021B (zh) * 2012-04-21 2015-10-28 通化济达医药有限公司 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AU2013352261B2 (en) 2012-11-29 2018-05-10 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
WO2014172432A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
EA030726B1 (ru) 2013-04-17 2018-09-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
EP4218763A1 (en) 2013-04-17 2023-08-02 Signal Pharmaceuticals, LLC 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one for treating glioblastoma multiforme
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
HK1221174A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和5-取代喹唑啉酮化合物的组合疗法
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
JP6401250B2 (ja) 2013-05-29 2018-10-10 シグナル ファーマシューティカルズ，エルエルシー ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
CN106008559B (zh) * 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
WO2018144791A1 (en) * 2017-02-03 2018-08-09 Millennium Pharmaceuticals, Inc. Combination of vps34 inhibitors and mtor inhibitors
MX2019015731A (es) 2017-06-22 2020-08-03 Celgene Corp Tratamiento de carcinoma hepatocelular caracterizado por infeccion por virus de hepatitis b.
RU2771201C2 (ru) * 2017-11-06 2022-04-28 Медшайн Дискавери Инк. ПИРИДОПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ВЫПОЛНЯЮЩИЕ ФУНКЦИЮ ДВОЙНЫХ ИНГИБИТОРОВ mTORC 1/2
WO2021133509A1 (en) * 2019-12-27 2021-07-01 Angex Pharmaceutical, Inc. Heterocyclic compounds as mtor inhibitors
AU2021207804A1 (en) 2020-01-13 2022-09-01 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
EP4161926A4 (en) * 2020-06-03 2024-06-19 Yumanity Therapeutics, Inc. PYRIDOPYRIMIDINES AND THEIR METHODS OF USE
EP4204412A4 (en) * 2020-08-26 2024-10-09 InventisBio Co., Ltd. HETEROARYL COMPOUNDS, PRODUCTION PROCESSES AND USES THEREOF
CN117088898A (zh) * 2022-05-13 2023-11-21 中国药科大学 稠环嘧啶类化合物及其制备方法、药物组合物和应用
WO2024057013A1 (en) * 2022-09-12 2024-03-21 Exscientia Ai Limited Nlrp3 modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) * 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US4560685A (en) * 1984-06-18 1985-12-24 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung 2-Piperazino-pteridines useful as antithrombotics and antimetastatics
DE3445298A1 (de) * 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
DE50008690D1 (de) * 1999-09-07 2004-12-23 Syngenta Participations Ag p-Tolyl-Heterocyclen als Herbizide
ES2360933T3 (es) * 2000-04-27 2011-06-10 Astellas Pharma Inc. Derivados de heteroarilo condensados.
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
GB0428475D0 (en) * 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders

Also Published As

Publication number Publication date
TW200738706A (en) 2007-10-16
CA2628920C (en) 2015-12-29
TWI452047B (zh) 2014-09-11
CA2628920A1 (en) 2007-05-31
HK1124039A1 (en) 2009-07-03
AU2006318948A1 (en) 2007-05-31
KR101464384B1 (ko) 2014-11-21
AR057626A1 (es) 2007-12-05
NO20082101L (no) 2008-08-15
HRP20120963T1 (hr) 2012-12-31
AU2006318948B2 (en) 2011-02-24
IL191196A (en) 2016-02-29
KR20080070079A (ko) 2008-07-29
NO341055B1 (no) 2017-08-14
PL1954699T3 (pl) 2013-01-31
US20080194546A1 (en) 2008-08-14
EP1954699B1 (en) 2012-09-19
WO2007060404A1 (en) 2007-05-31
ECSP088536A (es) 2008-07-30
JP2009516727A (ja) 2009-04-23
JP5161102B2 (ja) 2013-03-13
EP1954699A1 (en) 2008-08-13

Similar Documents

Publication Publication Date Title
UY29938A1 (es) Derivados de pirido-, pirazo- y pirimido-pirimidina y su uso como inhibidores de mtor
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
ECSP12012292A (es) Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
CL2012001056A1 (es) Compuestos derivados de cromenona sustituidos, inhibidores de enzimas pi 3 quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion de trastornos de proliferacion celular, tales como tumores enfermedades inflamatorias y fibroticas, asma, diabetes insulinodependiente, entre otras.
ECSP10010556A (es) Piridinas y pirazinas como inhibidores de pi3k
CR20120177A (es) Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes
CR11568A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su sintesis
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
ECSP066314A (es) Derivados piridilo y su uso como agentes terapéuticos
EA200701114A1 (ru) Азоловые производные с антимускариновой активностью
UY30327A1 (es) Nuevos compuestos ii
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
CU24087B1 (es) Compuestos de carbazol
CR10383A (es) Derivados triazolopirazina.
PA8680701A1 (es) Derivados de oxindol
CL2012000001A1 (es) Compuestos derivados de heteroarilo-pirazolopirimidina-carboxamida, inhibidores de jak; composicion farmaceutica que los comprende; utiles para el tratamiento de la artritis reumatoide, enfermedad de chron, dermatitis, psoriasis, entre otros.
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
UY30328A1 (es) Derivados de 2-piridona, procesos de preparacion, composiciones conteniéndolos y aplicaciones.
UY31299A1 (es) Nuevos inhibidores de catepsina y su uso
ECSP055572A (es) Derivados ciclotiocarbamativos como moduladores pr y el uso de los mismos en el tratamiento de enfermedades de la piel.
ECSP055575A (es) Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20161212